ABSTRACT -Chronic stimulus subsequent to cell injury plays an important role in cancer development, but the precise mechanisms remain unknown partly because appropriate animal models are lacking. In the present study, the effects of hepatotoxicant carbon tetrachloride (CCl 4 ) on in vivo mutagenicity were investigated using gpt delta mice with or without p53. Female B6C3F 1 p53-proficient or -deficient gpt delta mice were given a diet containing 300 ppm of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) for 13 weeks, concurrently with intraperitoneal injection of 1 ml/kg CCl 4 solution once a week. Mutant frequencies of gpt and red/gam in p53-proficient mice fed MeIQx were both significantly elevated by CCl 4 co-treatment. Enhancing effects of CCl 4 treatment were also noted in p53-deficient mice. In the mutation spectra analysis of gpt mutant colonies, G:C to T:A transversions were predominantly observed regardless of CCl 4 injection, and clonal expansion of gpt colonies were increased in the co-treated group as compared with MeIQx alone group. The present data showing no significant changes in mRNA expression levels of CYP1A2 and GSTa4 between MeIQx-treated groups with and without CCl 4 . In the Western blotting analysis, CYP1A2 protein levels were significantly decreased in the co-treated group as compared to MeIQx alone group, and GSTα protein levels were not changed among any groups. It is suggested that the mutant frequency by co-treatment with CCl 4 might result from some factors other than p53 or MeIQx metabolism/excretion. Thus, our data clearly demonstrate that this model could be a powerful tool for identifying the mechanisms underlying combinatorial effects on carcinogenesis.
INTRODUCTION
It has been widely recognized that chronic stimulus might play an important role in cancer development. For example, infection by the hepatitis C virus (HCV) is considered a trigger for development of hepatocellular carcinoma, in which the modes of action might involve cell injury and subsequent regenerative cell proliferation by HCV infection (Hayashi et al., 1999; Kato et al., 2003) . Alternatively, several cytokines released from inflammatory cells supposedly take part in carcinogenesis (Lu et al., 2006) . In the liver, TNF-α and IL-6 released from activated Kupffer cells are promising candidate contributing factors (Roberts et al., 2007) , because they could be Enhancing effects of carbon tetrachloride on in vivo mutagenicity in the liver of mice fed 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) key molecules that trigger a cascade causing cell proliferation in liver regeneration (Montes et al., 2006) . However, it remains uncertain as to which chronic stimulus related factors actually affect carcinogenesis at the molecular level, partly because of the absence of suitable animal models for simultaneously investigating the correlation between the two events.
Recently, rodents carrying reporter genes have attracted attention as useful tools to assess in vivo genotoxic as well as carcinogenic risk of environmental chemicals (Gorelick and Mirsalis, 1996; Nohmi et al., 2000; Nishikawa et al., 2001) . Such rodent bioassays conducted with similar protocols to the repeated dose toxicity study enable us to investigate the precise mechanisms underlying carcinogenesis. Up to now, along with the reporter gene mutation assay, we have shown that concurrent measurements of several parameters such as glutathione S-transferase placental form (GST-P) immunohistochemistry , bromodeoxyuridine (BrdU) labeling index , and levels of thiobarbituric acid-reactive substances and 8-hydroxydeoxyguanosine provide crucial information on the modes of action. Therefore, it is likely that the effects of alterations in the tissue microenvironment such as chronic inflammation on in vivo mutagenicity can be demonstrated by application of conventional transgenic rodents.
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) is one of the heterocyclic amines (HCAs) produced in cooked meat, inducing tumors in the liver, Zymbal gland, clitoral glands, and skin in rats, and in the liver, lung, hematopoietic system, and colon of mice (Ohgaki et al., 1987; Sugimura et al., 2004; Nishikawa et al., 2005) . In vivo mutagenicity of MeIQx in transgenic mice has also been reported in the liver (Itoh et al., 2000; . Carbon tetrachloride (CCl 4 ) is a potent hepatotoxicant in rodents, and single administration at higher doses causes extensive hepatocellular necrosis with inflammatory cell infiltration (Kim et al., 2009) .
In the present study, for developing an animal model using reporter transgenic mice, we examined the effects of CCl 4 -induced hepatic injury on in vivo mutagenicity of MeIQx in the liver of gpt delta mice. In addition, considering the enhancing effects of p53 deficiency in in vivo mutagenicity and tumorigenicity on tissue damage by dextran sulfate sodium-induced colitis model or helicobacter felis-infected mice model (Levine, 1997; Fujii et al., 2004; Chang et al., 2007; Jenks et al., 2003) , the same protocol was also performed in p53-deficient gpt delta mice.
MATERIAlS AND METhODS

Chemicals
MeIQx and CCl 4 were purchased from Toronto Research Chemicals (North York, Canada) and Wako Pure Chemical Industries (Osaka, Japan), respectively.
Animals and treatments
The protocol for this study was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences. Female B6C3F 1 gpt delta mice carrying 80 tandem copies of the transgene lambda EG10 in haploid genome were raised by mating C57BL/6 gpt delta and non-transgenic C3H/He mice (Japan SLC, Inc., Shizuoka, Japan). Heterozygous p53-deficient mice with a C57BL/6 background established by Tsukada et al. (1993) were crossed with C57BL/6 mice (Charles River Japan Inc., Kanagawa, Japan); then, heterozygous p53-deficient and wild-type mice were obtained from the F1 generation and genotyped by the polymerase chain reaction (PCR) on tail DNA. As shown in Fig. 1 , twenty female B6C3F 1 gpt delta mice were randomized by weight into 4 groups. Animals were housed in a room with a barrier system, and maintained under the following constant conditions: 23 ± 2ºC, 55 ± 5% relative humidity, ventilation frequency of 18 times/hr, and a 12 hr light-dark cycle with free access to CRF-1 basal diet (Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water.
Starting at 8-wk of age the gpt delta transgenic mice were fed a diet containing 300 ppm MeIQx or maintained as non-treatment controls for 13 weeks. To induce hepatic injury, mice were intraperitoneally injected with 1 ml/ kg CCl 4 solution (20 v/v% CCl 4 in corn oil) once a week from week 2. The dose and interval of CCl 4 administration were selected based on a study by Kato et al. (2003) , as conditions to recover from increased levels of serum alanine aminotransferase (ALT) to basal levels. All mice were sacrificed and a part of the left lateral lobe of the liver was preserved with an ISOGEN kit (Nippon Gene, Tokyo, Japan) and stored at -80ºC until used to isolate total RNA. The remaining liver was also stored at -80ºC for subsequent in vivo mutation assays. At autopsy, the body and liver weights were measured.
In vivo mutation assays
The 6-TG and Spi -selections were performed as previously described . Briefly, genomic DNA was extracted from the liver, and lambda EG10 DNA (48 kb) was rescued as lambda phage by in vitro packaging. For 6-TG selection, the packaged phage was incubated with E. coli YG6020, which expresses Cre recombinase, and converted to a plasmid carrying gpt and chloramphenicol acetyltransferase. Infected cells were mixed with molten soft agar and poured onto agar plates containing chloramphenicol and 6-TG. To determine the total number of rescued plasmids, 9,000-fold diluted phages were used to infect YG6020, and were poured on five plates containing chloramphenicol without 6-TG. Plates were incubated at 37ºC for selecting 6-TG-registant colonies. Positively selected colonies were counted on day 3 and collected on day 4 from all plates. The mutant frequency was calculated by dividing the number of gpt mutants by the number of rescued phages.
For Spi -selection, packaged phage was incubated with E. coli XL-1 Blue MRA for survival titration and E. coli XL-1 Blue MRA P2 for mutant selection. Infected cells were mixed with molten lambda-trypticase soft agar and poured onto lambda-trypticase agar plates. The next day, plaques (Spi -candidates) were punched out with sterilized glass pipettes and the agar plugs were suspended in SM buffer. To confirm the Spi -phenotype, suspensions were spotted on three plate types where XL-1 Blue MRA, XL-1 Blue MRA P2, or WL95 P2 strains were spread with soft agar. Real Spi -mutants, which made clear plaques on every plate, were counted.
For characterizing the mutation spectra of gpt mutants, a 739 bp DNA fragment containing the 456 bp coding region of gpt was amplified by PCR as described previously . DNA sequencing was carried out at the Dragon Genomics Center of Takara Bio (Mie, Japan). On the MeIQx alone and co-treatment groups, gpt mutants were analyzed only on one selected plate based on the assumption that the colony number on the selected plate was closest to the average number of five plates.
Quantitative real time RT-PCR
Total RNA was isolated by using the ISOGEN kit according to the manufacturer's instructions. RNA reverse transcription with random hexamers was performed using a High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). PCR was performed on an Applied Biosystems 7900HT FAST Real-Time PCR Systems (Applied Biosystems) with TaqMan ® Fast Universal PCR Master Mix (Applied Biosystems), TaqMan ® Gene Expression Assays (Applied Biosystems) and TaqMan ® Rodent GAPDH control reagents (Applied Biosystems). The assayed genes included cytochrome P450 family 1, subfamily A, polypeptide 2 (CYP1A2) and glutathione S-transferase alpha 4 (GSTα4). Rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control. The expression levels of the target genes CYP1A2 and GSTα4 were evaluated by a relative standard curve method.
Preparation of liver microsome and cytosol
For preparation of hepatic cytosol solutions and microsomal suspensions, liver samples were thawed on ice and homogenized in ice-cold 67 mM phosphate buffer (pH 7.5) containing 1.15% (w/v) KCl. Hepatic homogenates were centrifuged at 9,000 g for 20 min at 4ºC and supernatants were centrifuged at 105,000 g for 60 min at 4ºC. The supernatants were aliquoted and stored at -80ºC until use. The precipitates were homogenized with the phos- Twenty female p53-proficient or -deficient gpt delta mice with B6C3F 1 background were divided into 4 groups, each consisting 5 animals. Group 1 was fed a basal diet as non-treatment control for 13 weeks. Group 2 was fed a diet containing 300 ppm MeIQx for 13 weeks. Group 3 received CCl 4 solution (20 v/v% CCl 4 in corn oil) by i.p. injection once a week at a dose of 1 ml/kg from week 2. Group 4 was fed a diet containing MeIQx and injected CCl 4 in the same manner with group 2 or 3. All mice were sacrificed at the closed triangle time point.
phate buffer and centrifuged at 105,000 g for 60 min at 4ºC. The precipitates were suspended with phosphate buffer and stored at -80ºC until use.
Western blot analysis
Protein levels of CYP1A2 and GST were analyzed by Western blotting. CYP1A2 and GST proteins were measured in liver microsomes and cytosols. Rabbit anti-rat polyclonal antibody for CYP1A2 (Millipore Co., Billerica, MA, USA) and goat anti-rat polyclonal antibody for GST (Abcam, Cambridge, UK) were used as primary antibodies. Mouse monoclonal anti β-actin antibody (Sigma, St. Louis, MO, USA) was used as loading control. The liver microsomes and cytosols were separated by 10 or 12% Mini PROTEAN TGX gel (Bio-Rad Laboratories, Hercules, CA, USA), respectively, and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories). The membranes were blocked with 0.5% casein in PBS for 1 hr at room temperature. Primary antibodies diluted in 0.5% casein in PBS were hybridized for 1 hr at room temperature. After four washes in the wash buffer, membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 1 hr at room temperature. After four washes in wash buffer and twice in PBS, protein were detected by ECL PLUS Western Blotting Detection Reagent (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA), and band intensity was measured by ChemiDoc TM XRS+ system (Bio-Rad Laboratories).
Statistical evaluation
The Tukey test was used to compare liver and body weights, quantitative real-time RT-PCR, MFs and Western blotting analysis between groups.
RESUlTS
Body and liver weights
There were no significant changes in final body and liver weights among all genotype groups (Table 1) . However, significant increase of body weight in the MeIQx alone group, and significant decrease of relative liver weight in the MeIQx alone and MeIQx plus CCl 4 groups of p53-deficient mice were noted as compared with each treatment group in p53-proficient mice. The absolute liver weights were comparable between groups.
gpt and Spi -MFs in the liver
Data for gpt MFs in the liver of p53-proficient mice analyzed by 6-TG selection are summarized in Table 2 . In the gpt mutation assay, MF (8.39 ± 2.63) in mice fed MeIQx was significantly increased as compared to the basal diet control (0.20 ± 0.03). Also, co-treatment with MeIQx and CCl 4 caused marked elevation of MF (15.69 ± 2.69), which was 1.9-fold significantly higher than that in the MeIQx alone group. In the Spi -mutation assay, MFs of red/gam in mice fed MeIQx (MeIQx alone; 1.54 ± 0.48, MeIQx plus CCl 4 ; 4.16 ± 1.28) were significantly elevated as compared to the control (0.37 ± 0.13), the combined treatment 2.7-fold enhancing the increase of MF with sta- tistical significance (Table 3) . In p53-deficient mice, gpt and red/gam MFs showed a tendency similar to the p53-proficient mice (Tables 4 and  5 ). The gpt MFs in p53-deficient mice fed MeIQx (MeIQx alone; 7.40 ± 2.40, MeIQx plus CCl 4 ; 23.28 ± 8.19) were significantly increased as compared to the basal diet control (0.79 ± 0.36), 3.1-fold increase being observed in the co-treatment with MeIQx plus CCl 4 group as compared with MeIQx alone group. MFs of red/gam in mice fed MeIQ (MeIQx alone; 0.63 ± 0.49, MeIQx plus CCl 4 ; 1.75 ± 0.66) were elevated without or with statistical significance as compared to the control (0.38 ± 0.29). The cotreatment with MeIQx and CCl 4 caused marked elevation of MF, which was 2.8-fold significantly higher than that in the MeIQx alone group. No difference of these MFs was seen between genotypes.
gpt mutation spectra analysis
To characterize gpt mutations in the liver of p53-proficient mice, DNA sequencing was performed (Table  6 ). In control mice, G:C to A:T transitions predominated (5/15 = 33.3%). In the CCl 4 alone group, G:C to T:A transversions (8/21 = 38.1%) and G:C to A:T transitions (9/21 = 42.9%) were observed at about the same frequency. On the other hand, the predominant spectra of colonies with gpt mutation were G:C to T:A transversions in mice treated with MeIQx regardless of CCl 4 treatment (MeIQx alone group: 34/58 = 58.6%, MeIQx plus CCl 4 group: 54/111 = 48.6%). In addition, clonal expansions of gpt mutant colonies more frequently occurred in the MeIQx plus CCl 4 treated group compared to the MeIQx alone group. In the co-administered group, 119/182 of mutant colonies with G:C to T:A transitions were identified; however, 53/81 were identified in the MeIQx alone group (unpublished data). Spectra analysis was not done in the p53-deficient mice.
Expression levels of CYP1A2 and GSTα4 mRNA Expression levels of CYP1A2 and GSTα4 in the liver of p53-proficient mice are shown in Fig. 2 . Expression levels of CYP1A2 were significantly increased in MeIQx alone and co-treatment groups as compared to basal control or CCl 4 injected groups. There were no significant changes in CYP1A2 levels among MeIQx alone and co-treatment groups (p < 0.01). Significant changes in GSTα4 expression levels were not observed among any groups (p < 0.01).
Expression levels of CYP1A2 and GSTα protein
Expression level of CYP1A2 and GSTα protein in the liver of p53-proficient mice are shown in Fig. 3 . Expression levels of CYP1A2 were significantly decreased in the co-treated group as compared to MeIQx alone group (p < 0.05). Also, CYP1A2 levels in the co-treatment groups were significantly decreased as compared to basal control group (p < 0.05). Although GSTα protein expression levels were decreased in CCl 4 alone group as compared to other groups, no statistical significances were observed among any groups.
DISCUSSION
In the present study, 13-week feeding of MeIQx caused significant elevation of gpt MFs in the livers of p53-proficient gpt delta mice. In the mutation spectra analysis of gpt mutant colonies, G:C to T:A transversions were predominantly observed, which is in line with a previous report . Thus, the present data clearly demonstrated that co-treatment with CCl 4 could further enhance gpt MFs due to MeIQx; their mutation spectra were almost identical to those in the MeIQx alone group. It is well known that MeIQx incurs N-hydroxylation by CYP 1A1/2 followed by further activation due to O-acetyltransferase or sulfotransferase (Shimada et al., 1989; Rich et al., 1992; Turesky et al., 1998), giving rise to N-(deoxyguanosine-8-yl)-MeIQx, N-(deoxyguaonosine-8-yl )-4,8-DiMeIQx and N 2 -(deoxyguanosine-8-yl)-MeIQx (Schut and Snyderwine, 1999; Snyderwine et al., 1993; Ochiai et al., 1993) . These bulky adducts for guanine are believed to be responsible for G:C to T:A transversions . On the other hand, MeIQx-DNA adduct formation was effectively inhibited by purpurin, an inducer of phase II enzymes, such as GST and UDP-glucuronyltransferase (Takahashi et al., 2007) , implying that MeIQx is conjugated and excreted by these enzymes. Our real-time RT-PCR analysis demonstrated that there were no changes in mRNA levels of CYP1A2 and GSTα4 between MeIQx-treated mice with and without CCl 4 treatment. Likewise, no differences in the O-acetyltransferase or sulfotransferase mRNA levels were observed regardless of CCl 4 injection (data not shown). Moreover, CYP1A2 protein levels were not elevated, rather decreased, in co-treatment group as com- pared with MeIQx alone group and GSTα protein levels were not changed regardless of CCl 4 injection, suggesting no remarkable effects of co-administration of CCl 4 to enhance MeIQx metabolism/excretion. CCl 4 is used to induce experimental hepatic injury. To mimic chronic hepatic inflammation, mice were intraperitoneally injected with 1 ml/kg CCl 4 solution once a week for 12 weeks. Elevated serum ALT levels return to a normal range 4 days after CCl 4 administration in the liver of C57BL/6 mice (Kato et al., 2003) . In addition, single i.p. administration of CCl 4 induces histological changes including inflammatory cell infiltration in the mouse liver (Kim et al., 2009) . Kupffer cell activation is a crucial event in hepatocyte injury induced by CCl 4 and activated Kupffer cells release cytokines such as TNF-α and IL-6, which are important factors for hepatocyte regeneration (Taub et al., 1999) . It is reported that MeIQx is an initiator in the resistant hepatocyte model, and induces γ-glutamyltransfertase positive hepatic foci in rat liver (Kleman et al., 1989) . Also, it has been demonstrated that co-administration with MeIQx and CCl 4 induced development of GST-P positive foci, as a precancerous lesion, in the liver compared to MeIQx only treated rats (Sone et al., 1992; Iwai et al., 2002) . However, combined treatment with MeIQx and CCl 4 failed to enhance MeIQx-DNA adducts levels (Sone et al., 1992) . Iwai et al. (2002) demonstrated that repeated co-administration with CCl 4 enhanced the BrdU-labeling index in rat liver. These data suggest that development of precancerous lesions is caused by acceleration of cell turnover due to liver injury by CCl 4 , but not caused by enhancement of in vivo mutagenicity of MeIQx. In the present study, gpt MFs were enhanced by concurrent administration with CCl 4 without biological significant changes in mRNA and protein levels related to MeIQx metabolism/excretion. The gpt mutant spectra analysis revealed increased clonal expansion of gpt colonies in the combined treatment group. Our data suggest that induction of cell proliferation may play an important role in mutagenicity of MeIQx. In the present study, slight inflammatory cell infiltration was observed in the liver of CCl 4 treated mice (data not shown), the change may suggest that the hepatic injury was caused by CCl 4 injection. However, we could not detect induction of cell proliferation due to CCl 4 injection by immunohistochemical staining for proliferation cell nuclear antigen (data not shown). It was reported that the cell-proliferative activity is increased, and returns to a normal level 6 days after CCl 4 single injection in rats and mice (Zhou et al., 2006) . Because we have examined induction of cell proliferation at 7 day after final administration of CCl 4 , it might have been a time lag to observe the cell proliferation.
In the Spi -mutation assay, MeIQx caused significant elevation of red/gam MFs in the livers of p53-proficient gpt delta mice. This result indicates that MeIQx caused not only point mutations but also deletion mutations in the mouse liver. Like the gpt assay, the same tendency was observed in the Spi -assay, in which MFs in the co-treatment group were higher than in the MeIQx alone group. Similar results were reported in the liver and colon in the gpt delta transgenic mice treated by other HCAs, such as 9-(4'-aminophenyl)-9H-pyrido [3,4-b] indole and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine . Chronic inflammation causes DNA damage by reactive oxygen and nitrogen species produced by neutrophils and macrophages (Lu et al., 2006) . In the present study, since CCl 4 alone did not increase MFs, DNA damage did not occur with this CCl 4 dose. Therefore, the relation of hepatic injury and deletion mutations was clear, but it was thought that increased MFs of red/ gam would have resulted from cell proliferation induced by CCl 4 . p53 is a tumor suppressor protein and plays a key role in several pathways including inflammatory responses (Hussain and Harris, 2006) . Inflammatory stress activates p53, and a DNA damaged cell is repaired or removed through induced pathways such as cell cycle arrest, DNA repair and apoptosis. In the present study, the gpt and Spiassay of p53-deficient mice showed similar results to p53-proficient mice. Mice heterozygous for p53 did not have sensitivity to carcinogenicity of MeIQx in a 1-year study (Park et al., 1999) , and our in vivo mutation assay results reflect this lack of sensitivity. The Spi -MFs in the cotreated group were not significantly different as compared with the MeIQx alone or control group. These data suggested that the p53-deficient mice had a different sensitivity for the type of mutation induced by MeIQx treatment.
In conclusion, repeated hepatic injury due to CCl 4 might have increased gpt and red/gam mutation frequencies in the livers of gpt delta mice treated with MeIQx. Although further studies are needed to investigate molecular mechanisms underlying the enhancing effects of CCl 4 -induced liver injury on MeIQx genotoxicity, our data clearly demonstrate that this model could be a powerful tool for correlating events between inflammation and carcinogenesis.
